Loading...
XHKG3933
Market cap2.75bUSD
Dec 23, Last price  
11.74HKD
1D
3.89%
1Q
29.72%
Jan 2017
122.35%
IPO
261.23%
Name

United Laboratories International Holdings Ltd

Chart & Performance

D1W1MN
XHKG:3933 chart
P/E
7.42
P/S
1.46
EPS
1.49
Div Yield, %
2.73%
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
12.84%
Revenues
13.74b
+21.22%
2,086,097,2162,430,926,9343,307,047,9564,088,081,9545,541,863,1925,183,778,6825,653,764,4645,971,793,4366,422,409,9616,445,983,2436,077,944,0006,826,645,0007,510,586,0008,392,600,0008,772,488,0009,703,438,00011,334,262,00013,739,879,000
Net income
2.70b
+70.85%
174,307,439478,199,761378,765,722476,713,112830,200,94584,391,079130,422,79237,536,441544,615,84492,411,554-272,363,00081,758,000682,928,000641,764,000702,989,000988,098,0001,581,094,0002,701,350,000
CFO
2.44b
+20.14%
286,241,898337,572,611610,511,854653,134,902569,463,560411,542,580475,737,1771,155,133,1161,400,007,7651,515,919,1521,074,464,000769,945,0001,213,239,0001,801,184,0001,567,826,0001,542,551,0002,030,543,0002,439,438,000
Dividend
Sep 19, 20240.16 HKD/sh
Earnings
Mar 24, 2025

Profile

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
URL
http://www.tul.com.cn/
IPO date
Jun 15, 2007
Employees
14,000
Domiciled in
HK
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
13,739,879
21.22%
11,334,262
16.81%
9,703,438
10.61%
Cost of revenue
10,545,948
9,324,659
8,289,425
Unusual Expense (Income)
NOPBT
3,193,931
2,009,603
1,414,013
NOPBT Margin
23.25%
17.73%
14.57%
Operating Taxes
643,303
425,743
213,062
Tax Rate
20.14%
21.19%
15.07%
NOPAT
2,550,628
1,583,860
1,200,951
Net income
2,701,350
70.85%
1,581,094
60.01%
988,098
40.56%
Dividends
(581,448)
(272,636)
(220,847)
Dividend yield
4.56%
3.06%
2.75%
Proceeds from repurchase of equity
(1,880)
(31,619)
BB yield
0.02%
0.39%
Debt
Debt current
200,362
1,363,102
1,613,777
Long-term debt
1,310,153
1,103,429
232,208
Deferred revenue
43,413
55,319
Other long-term liabilities
339,508
(237,482)
(227,628)
Net debt
(2,759,278)
(2,284,201)
(1,485,524)
Cash flow
Cash from operating activities
2,439,438
2,030,543
1,542,551
CAPEX
(1,274,484)
(779,548)
(482,168)
Cash from investing activities
(1,556,950)
(594,919)
(587,224)
Cash from financing activities
(1,362,678)
(24,166)
(620,926)
FCF
491,063
1,097,352
1,047,724
Balance
Cash
4,261,989
4,743,071
3,331,009
Long term investments
7,804
7,661
500
Excess cash
3,582,799
4,184,019
2,846,337
Stockholders' equity
7,312,960
6,886,949
5,575,295
Invested Capital
11,008,011
8,563,480
8,141,144
ROIC
26.06%
18.96%
14.84%
ROCE
21.89%
15.53%
12.67%
EV
Common stock shares outstanding
1,817,027
1,819,730
1,840,043
Price
7.01
43.06%
4.90
12.39%
4.36
-20.44%
Market cap
12,737,359
42.85%
8,916,677
11.14%
8,022,587
-17.10%
EV
9,990,921
6,633,821
6,536,479
EBITDA
3,759,579
2,544,379
2,021,166
EV/EBITDA
2.66
2.61
3.23
Interest
66,896
81,595
60,231
Interest/NOPBT
2.09%
4.06%
4.26%